SHIRE PLC (NASDAQ:SHPG) Files An 8-K Other Events
Item 8.01. Other Events
Shire plc has issued the press releases attached hereto as Exhibits 99.1, 99.2, 99.3 and 99.4, which are incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. The following exhibits are filed herewith:
EXHIBIT INDEX
Shire plc Exhibit
EX-99.1 2 december212018-holdingcoxe.htm EXHIBIT 99.1 Exhibit EXHIBIT 99.1Press Releasewww.shire.com Holding(s) in CompanyDecember 21,…
To view the full exhibit click here
About SHIRE PLC (NASDAQ:SHPG)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
